Fosamax Pre-Surgery Hold Window: What Surgeons and Patients Need to Know About Alendronate

Why the Pre-Surgery Hold Question Comes Up

Surgeons and dentists see alendronate-treated patients often. Oral bisphosphonates like alendronate are among the more commonly prescribed osteoporosis medications in the United States, and clinicians should confirm current prescribing volume against surveillance sources such as the CDC's National Center for Health Statistics data briefs rather than relying on a single fixed figure, since a precise national prescription count could not be independently confirmed for this draft.

When a patient on long-term Fosamax needs a dental extraction, joint replacement, or jaw surgery, the underlying question is a genuine trade-off: a theoretical reduction in jaw bone healing complications on one side, and a real fracture risk from stopping a working medication on the other.

The Pharmacokinetic Reality

Understanding alendronate's pharmacology is the starting point. After oral absorption, a substantial portion of the drug that reaches the bloodstream is taken up by bone and incorporated into hydroxyapatite crystal within about a day; the remainder is excreted renally unchanged [1]. The skeletal half-life has been estimated at more than 10 years in humans, meaning stopping alendronate does not appreciably change bone drug concentration in the weeks surrounding an elective procedure [2].

This long half-life is the central reason the American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper concludes that a short-term drug holiday is unlikely to meaningfully change bone drug levels around the time of most surgeries [3].

Fracture Risk Does Not Disappear at the Surgical Admission Door

Patients prescribed alendronate have osteoporosis or significant osteopenia by definition. The Fracture Intervention Trial (FIT), which enrolled women with existing vertebral fractures (N=2,027), found that alendronate 10 mg daily over 3 years reduced new vertebral fractures by 47% compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68, P<0.001) [4]. Stopping that protection without a clear reason exposes an already fragile skeleton to additional risk, particularly around surgery, when falls, immobility, and reduced intake can compound baseline vulnerability.

Alendronate's Mechanism and Why It Complicates Surgical Healing

Alendronate is a nitrogen-containing bisphosphonate. It inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway inside osteoclasts, causing osteoclast apoptosis and a net reduction in bone resorption [5]. This is what makes it effective against osteoporotic fracture, and also what raises questions around procedures that depend heavily on new bone formation.

Suppression of Bone Remodeling

Normal fracture repair and osseointegration, which matter for dental implants and some orthopedic fixation, depend on a remodeling cycle: osteoclast-driven resorption creates space that osteoblasts then fill with new bone. Bisphosphonate therapy blunts osteoclast activity, which may slow remodeling-dependent healing in some patients. Some smaller studies and reviews have reported modestly higher implant failure rates in bisphosphonate-exposed patients compared with unexposed patients, with the absolute difference generally described as small.

Medication-Related Osteonecrosis of the Jaw (MRONJ)

MRONJ is the complication clinicians worry about most in this context. It is defined as exposed bone, or bone that can be probed through a fistula, in the maxillofacial region, present for more than 8 weeks in a patient receiving or previously exposed to antiresorptive therapy, without a history of radiation to the jaw [3].

For oral bisphosphonates, AAOMS estimates MRONJ incidence at roughly 0.01% to 0.1% [3], far lower than the range reported with high-dose intravenous bisphosphonates used in oncology. Duration of oral bisphosphonate therapy beyond about 4 years and concurrent corticosteroid use are the risk factors most consistently identified in observational data.

The Serum CTX Controversy

Some clinicians have used serum C-terminal telopeptide (CTX) as a surrogate marker of bone turnover suppression before elective dental surgery, with a threshold around 150 pg/mL sometimes cited informally as a minimum considered acceptable for extraction. AAOMS's 2022 position paper states that CTX has not been validated as a reliable predictor of MRONJ risk and no longer recommends its routine use in surgical decision-making [3]. Clinicians who still order it should treat a result as one data point in the overall clinical picture, not a binary green light, and the specific 150 pg/mL figure should be treated as informal practice rather than a validated cutoff.

Current Guideline Recommendations on Holding Alendronate

No single authoritative body has issued a randomized-trial-backed universal hold window for alendronate before all surgery types. The guidance that exists is largely expert consensus.

AAOMS 2022 Position Paper

AAOMS's 2022 update indicates that most patients who have taken oral bisphosphonates for under 4 years, with no additional clinical risk factors, generally do not need their planned surgery delayed or altered because of the medication. For patients on therapy longer than 4 years, or with concurrent corticosteroid use, the paper describes a temporary drug holiday of around 2 months before and after elective invasive procedures as a reasonable option to discuss, while explicitly noting that direct outcome evidence supporting this practice is limited [3].

This reflects a recognition that the drug's skeletal half-life makes brief holidays pharmacologically questionable, while still giving clinicians a conservative framework for higher-risk patients.

American Society for Bone and Mineral Research (ASBMR) Drug Holiday Guidance

An ASBMR-affiliated discussion of long-term bisphosphonate therapy, published in the New England Journal of Medicine, describes reassessing bisphosphonate need after roughly 3 to 5 years in lower-risk patients (for example, femoral neck T-score above -2.5 after treatment) and later in higher-risk patients, with a drug holiday of 1 to 2 years considered reasonable for lower-risk patients [7]. This guidance is about long-term disease management rather than surgical timing specifically, but it supports the general point that alendronate's skeletal effect persists well beyond the day someone stops taking it.

Orthopedic Surgery Context

For joint replacement and other orthopedic procedures, bisphosphonate use does not appear to meaningfully compromise implant integration in the short term. A population-based cohort study found no significant difference in revision risk between bisphosphonate users and non-users after hip or knee arthroplasty [8]. The exact cohort size, country, and follow-up duration reported in that study should be confirmed directly before being cited as specific figures; the source link is retained here for that verification. Routine pre-operative holds before orthopedic surgery are not a standard recommendation from orthopedic surgical societies.

The Fracture Risk Side of the Equation

Every conversation about holding alendronate should include a frank discussion of what stopping means for fracture risk.

Post-Discontinuation Bone Loss

An analysis of the Fracture Intervention Trial Long-Term Extension (FLEX, N=1,099) found that women who stopped alendronate after 5 years of treatment lost bone mineral density at the femoral neck over the following years at a faster rate than women who continued therapy, with measurable bone turnover changes beginning within about a year of stopping [9]. In that extension, hip fracture risk did not rise significantly among lower-risk women who paused, though vertebral fracture risk rose modestly in some analyses.

Who Cannot Safely Pause

Patients with any of the following characteristics face meaningful fracture risk during even a short alendronate hold:

• Femoral neck T-score below -2.5 despite treatment
• Prior fragility fracture of the spine or hip
• Older age combined with other fracture risk factors
• High falls risk combined with low bone density
• Concurrent systemic corticosteroid use at higher chronic doses

For these patients, the potential MRONJ benefit of a temporary dental hold needs to be weighed carefully against the fracture risk of stopping, and in many cases procedures should be planned around continued alendronate therapy rather than the reverse.

Shared Decision-Making Is Not Optional

Bone health guidance from professional osteoporosis organizations consistently emphasizes that treatment decisions should weigh the patient's fracture risk, other health conditions, and personal preferences together, rather than following a fixed rule. Stopping a medication with a documented 47% relative reduction in vertebral fractures in the trial population described above [4] is a meaningful clinical action. Patients deserve a documented conversation about this trade-off before any hold is initiated.

A Practical Decision Framework for Clinicians and Patients

The framework below organizes the small number of facts that actually change the recommendation: procedure risk, duration of alendronate use, corticosteroid exposure, and underlying fracture risk. It is meant to structure the conversation between prescriber, surgeon or dentist, and patient, not to replace individualized clinical judgment, and it should be reviewed by a qualified clinician before use in practice.

Step 1: Classify Procedure Risk

Lower-risk procedures (simple dental fillings, non-surgical periodontal therapy, routine minor orthopedic injections): a hold is not generally indicated regardless of alendronate duration.

Moderate-risk procedures (single-tooth extraction, minor soft-tissue oral surgery, less invasive orthopedic procedures): proceeding without a hold is reasonable if alendronate duration is under about 4 years and there is no corticosteroid use. If duration exceeds 4 years, discuss an optional temporary hold with the prescribing physician rather than deciding unilaterally.

Higher-risk procedures (multiple extractions, full-arch dental implants, major jaw surgery, bone grafting): involve the prescribing physician before the procedure. For patients on alendronate under 4 years with no added risk factors, proceeding with close monitoring is often reasonable. For patients on alendronate 4 or more years, or with corticosteroid use, a temporary hold before and after surgery may be discussed if fracture risk allows it.

Step 2: Weigh Fracture Risk Before Any Hold Is Considered

A formal fracture risk estimate (for example, using a validated tool such as FRAX) should inform this discussion. Patients with a high estimated 10-year hip or major osteoporotic fracture probability should not have alendronate held without input from an endocrinologist, rheumatologist, or other bone health specialist, since the fracture-risk cost of stopping may outweigh a still-unproven MRONJ benefit.

Step 3: Document the Decision

The chart should record the indication for holding or continuing, the estimated fracture risk, the procedure risk category, any alternatives discussed, and a specific plan for when alendronate will be restarted if it is held.

Step 4: Restart Timing

If a hold was implemented, alendronate is typically restarted once surgical site healing is confirmed, commonly around 6 to 8 weeks post-operatively. Delayed healing or a diagnosis of MRONJ requires continued hold and referral to a specialist rather than an automatic restart on a fixed schedule.

What the Evidence Actually Shows About Pausing Before Dental Surgery

The clinical literature on preventing MRONJ through drug holidays is limited to retrospective series, smaller prospective cohorts, and expert consensus. No randomized controlled trial has demonstrated that a pre-surgical drug holiday reduces MRONJ incidence in oral bisphosphonate users.

A retrospective cohort analysis of patients who underwent tooth extraction while on oral bisphosphonates found a small number of MRONJ cases, concentrated among those with the longest duration of therapy; the study did not show that shorter drug holidays reduced MRONJ incidence compared with continuing therapy, which is consistent with alendronate's long skeletal half-life.

A prospective observational study of dental extractions in bisphosphonate-exposed patients found a low overall MRONJ rate that was not clearly associated with whether a drug holiday had been observed.

These findings do not prove holds are useless for every patient. They do mean that a temporary pause, where one is recommended, rests on biological plausibility and expert consensus rather than direct trial evidence that it reduces harm.

Alendronate Efficacy Context: Why This Drug Is Still Widely Prescribed

Before discussing when to hold alendronate, it helps to remember why it is prescribed. The FIT trial arm enrolling women with existing vertebral fractures (N=2,027) is the source of the widely cited 47% relative reduction in vertebral fractures over 3 years (RR 0.53, 95% CI 0.41 to 0.68) [4]. A related arm of the same trial program enrolled women without pre-existing vertebral fractures and separately examined non-vertebral and hip fracture outcomes. That companion data appears to be indexed in JAMA, but the specific article and its exact figures were not independently confirmed for this draft; the editor should verify the source before any hip-fracture-specific percentage is published under this article. See this JAMA index entry, flagged here as unverified.

Alendronate's low cost, oral administration, and long post-marketing safety record support its use as a recommended first-line agent by the American College of Physicians for many women with osteoporosis at high fracture risk [12].

Long-Term Safety Profile

Concerns about atypical femoral fractures (AFF) and MRONJ emerged after widespread long-term use. A systematic review and meta-analysis pooling multiple bisphosphonate cohorts found that absolute AFF risk rises with duration of use, reaching an order of magnitude around the low hundreds per 100,000 patient-years among patients with 8 or more years of exposure, though estimates varied across the underlying studies [13]. This should be treated as a general estimate rather than a precise figure until the original review is checked directly. This uncertainty is one reason ASBMR-affiliated guidance recommends reassessing treatment need after several years rather than continuing indefinitely.

Dosing Reminders Relevant to Perioperative Management

The standard alendronate regimen is 70 mg once weekly. Patients must take it with 6 to 8 ounces of plain water, remain upright for at least 30 minutes, and delay food and other medications afterward. If a patient is unable to take oral medications (NPO) on their scheduled dose day around the time of surgery, the usual approach is to simply skip that dose and resume the following week, since there is no established practice of bridging with an intravenous bisphosphonate for a missed oral dose.

Special Populations

Patients on Glucocorticoids

Glucocorticoid-induced osteoporosis is itself a separate indication for bisphosphonate therapy. The American College of Rheumatology's glucocorticoid-induced osteoporosis guideline recommends bisphosphonate therapy for higher-risk patients on chronic glucocorticoids, though the exact dose and duration thresholds vary by age and risk category and should be confirmed against the current ACR guideline rather than a single simplified number [14]. These patients face compounded risk: the underlying inflammatory disease, steroid-induced bone loss, and sometimes immunosuppression that can impair wound healing. Hold decisions in this group benefit from direct coordination between the prescribing rheumatologist, the surgeon or dentist, and, where relevant, an endocrinologist.

Renal Impairment

Alendronate is contraindicated when estimated glomerular filtration rate (eGFR) is below 35 mL/min/1.73m². Patients in this range who are already on the drug perioperatively present a separate challenge, since nephrotoxic anesthetic agents and IV contrast used in surgery may further compromise renal function. The perioperative team should review eGFR close to the time of surgery and document whether alendronate is appropriate to continue.

Postmenopausal Women Under 65

Younger postmenopausal women on alendronate tend to have shorter cumulative exposure and lower MRONJ risk. For example, a woman in her late 50s on weekly alendronate for 2 years facing a single dental extraction generally does not need a hold under current guidance, since her procedure risk is low and her cumulative drug exposure is below the range where MRONJ risk becomes a stronger consideration.

Communicating the Hold Decision to Patients

Patients often encounter conflicting information. Their dentist may suggest stopping the drug; their prescribing physician may recommend continuing it. A clear, written explanation helps. The conversation should cover:

1. What alendronate does for their bones, in terms specific to their trial population and risk level rather than a single blanket number
2. Why a short pause does not meaningfully change drug levels already stored in bone
3. The low absolute MRONJ risk with oral bisphosphonates, roughly 0.01% to 0.1% per AAOMS [3]
4. The specific recommendation for their procedure, given their duration of use and other risk factors
5. When alendronate would be restarted if a hold is agreed upon

Patients who understand these points are more likely to follow a thoughtful plan and less likely to stop their medication unilaterally out of unfounded fear.

Monitoring After Surgery in Alendronate-Treated Patients

Post-operative follow-up for alendronate-treated patients should include a wound check around 1 to 2 weeks and a healing confirmation around 6 to 8 weeks, with documentation of the alendronate restart date if the drug was held. Any exposed bone, pain, or delayed healing beyond 8 weeks should prompt referral to an oral and maxillofacial surgeon or bone specialist for MRONJ evaluation. Early-stage MRONJ, meaning asymptomatic exposed bone only, can sometimes be managed conservatively with measures such as chlorhexidine rinses and close monitoring rather than immediate surgical debridement, under specialist guidance.